Botulinum toxin market Emerging Trends, Business Growth Opportunities, Major Driving Factors


Botulinum toxin market Emerging Trends, Business Growth Opportunities, Major Driving Factors

.

The Botulinum toxin market is projected to reach US$ 8,977.62 million by 2028 from US$ 5,307.71 million in 2021. It is expected to grow at a CAGR of 7.8% from 2021 to 2028. 

Botulinum toxins are neurotoxins that attack nerves and cause muscle paralysis. A bacterium known as clostridium botulinum makes these neurotoxins. Healthcare providers use specific bacteria for medical injections. Injections of botulinum toxin block nerve signals to the muscle injected into it. Without a signal, the muscle cannot contract. The result is a reduction in unwanted facial lines or features. Botulinum toxin injections like Botox and Dysport improve the appearance by relaxing the muscles that cause wrinkles. These injections also treat migraines, hyperhidrosis, overactive bladder, and eye problems.

In neurorehabilitation, BTX is mainly used to treat spasticity and prevent muscle contractures. Two formulations of BTX-A have been commercialized and marketed as Dysport (Ipsen Ltd., Berkshire, UK) and Xeomin (Merz, Frankfurt, Germany). Different procedures are used to manufacture BTX-A, and the drug also has different formulations and potencies, which are determined by biological assays based on their clinical use. BTX-B is distributed under the name of NeuroBloc in Europe. BTX has revolutionized the treatment of various spastic eye disorders, facial dystonia, and periocular folds. The precise knowledge and understanding of the functional anatomy of the facial muscles are necessary for ensuring the appropriate use of BTX in clinical practice. In the future, the development of new potent toxins for increasing potency and duration of action will offer lucrative opportunities for the botulinum toxin market to expand in different regions.

AbbVie Inc.; Merz Pharma; Medytox; Sanofi; Ipsen Pharma; Galderma; Revance Therapeutics Inc.; Lanzhou Institute of Biological Products Co., Ltd.; Candela Medical; and Daewoong Pharmaceutical Co. Ltd. are among the leading companies operating in the global botulinum toxin market.

Based on product type, the botulinum toxin market is segmented into type A botulinum toxin and type B botulinum toxin. Based on application, the market is segmented into medical and aesthetics. Based on end user, the botulinum toxin market is segmented into specialty and dermatology clinics, hospitals and clinics, and others. By geography, the market is segmented into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, and the Rest of APAC), Middle East Africa (Saudi Arabia, the UAE, South Africa, and the Rest of MEA), and South and Central America (Brazil, Argentina, and the Rest of SCAM).

Get sample PDF Copy of Botulinum toxins Industry at: https://www.theinsightpartners.com/sample/TIPRE00027431/

Company Profiles In Botulinum Toxin Market

  • AbbVie Inc.
  • Merz Pharma
  • Medytox
  • Sanofi
  • Ipsen Pharma
  • Galderma
  • Revance Therapeutics Inc.
  • Lanzhou Institute of Biological Products Co., Ltd.
  • Candela Medical
  • Daewoong Pharmaceutical Co. Ltd.

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:

If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Sameer Joshi

E-mail: sales@theinsightpartners.com

Phone: +1-646-491-9876

Read more

Comments